Source: International Congress 2017 – What is new in COPD diagnosis and classification?
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Ferguson (Farmington Hills, United States of America). The impact of grouping patients by the 2017 GOLD COPD strategy on response to therapy: post hoc results from the TONADO tiotropium+olodaterol trials. 3634

Member's Comments

No comment yet.

Related content which might interest you: Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials Source: International Congress 2017 – COPD management: new findings from large studies Year: 2017 Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study Source: ERJ Open Res, 5 (1) 00243-2018; 10.1183/23120541.00243-2018 Year: 2019 Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy Source: International Congress 2017 – COPD management Year: 2017 ICS withdrawal and exacerbation risk by GOLD 2017 Report: post hoc analysis of the WISDOM trial Source: International Congress 2018 – Primary care management of respiratory conditions Year: 2018 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Classifying patients as GOLD A–D using the 2017 strategy criteria: impact on efficacy by GOLD stage in the OTEMTO tiotropium+olodaterol clinical trials Source: International Congress 2017 – What is new in COPD diagnosis and classification? Year: 2017 Characterising patients with COPD by baseline short-acting ß2-agonist (SABA) use: a post hoc analysis of the EMAX trial Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Efficacy of revefenacin based on GOLD 2017 categories: reanalysis of phase 3 data in patients with COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Dyspnoea and clinical outcome in critically ill patients receiving noninvasive support for COVID-19 respiratory failure: post hoc analysis of a randomised clinical trial Source: ERJ Open Res, 7 (4) 00418-2021; 10.1183/23120541.00418-2021 Year: 2021 Nintedanib in IPF: post hoc analysis of the Italian FIBRONET observational study Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Two versus three months rehabilitation with the same number of sessions in patients with moderate to severe COPD: analysis of the results Source: Eur Respir J 2004; 24: Suppl. 48, 244s Year: 2004 Rehabilitation programs in patients in different severity stage of COPD (GOLD II-to-IV): analysis of the results Source: Eur Respir J 2005; 26: Suppl. 49, 69s Year: 2005 Bronchodilation or pulmonary rehabilitation:which test of exercise performance yields the greatest response for patients with stable COPD? An RCT. Source: International Congress 2018 – Additional latest insights in pulmonary rehabilitation for chronic lung diseases Year: 2018 Revefenacin (REV) improves health status and dyspnea regardless of baseline symptom status in chronic obstructive pulmonary disease (COPD): a post hoc analysis of phase 3 trials Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020 Validation of the codex index in patients with COPD enrolled in randomized clinical trials: A post-hoc analysis of the trilogy, trinity and tribute studies. Source: Virtual Congress 2020 – New tools for risk stratification of obstructive diseases Year: 2020 The effect of outpatient pulmonary rehabilitation on COPD assessment test (CAT) and GOLD classification – A retrospective data analysis Source: International Congress 2015 – Latest insights into pulmonary rehabilitation Year: 2015 Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Indacaterol/glycopyrronium (IND/GLY) improves lung function irrespective of gender baseline differences in patients with COPD: A pooled analysis from the IGNITE Program Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Characteristics of effective self-management interventions in patients with COPD: individual patient data meta-analysis Source: Eur Respir J 2016; 48: 55-68 Year: 2016